Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Enbrel Focus Includes Push For Earlier Treatment Of RA Patients

Executive Summary

Amgen's marketing strategy for Enbrel (etanercept) includes closing the gap between diagnosis and initiation of therapy in patients with moderate rheumatoid arthritis
Advertisement

Related Content

Wyeth/Amgen Enbrel Adds 25,000 Patients In Q1; Prevnar Back Orders Cleared
Wyeth/Amgen Enbrel Adds 25,000 Patients In Q1; Prevnar Back Orders Cleared
TNF inhibitor safety
Amgen Enbrel Injects Marketing Push: DTC Effort Counters Humira Launch
Amgen/Wyeth Enbrel Supplies Replenished With Rhode Island Plant Approval
Abbott Humira Marketing Will Challenge RA Competitors On Dosing, Efficacy
Immunex Enbrel Patient Starts After Jan. 1 Will Be Via Waiting List
Advertisement
UsernamePublicRestriction

Register

PS041334

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel